Related Experiment Video
Updated: Sep 20, 2025
Harnessing the Power of MicroRNA Cargoes in Small Extracellular Vesicles Released from Fresh-Frozen Human Brain Sections
Published on: November 8, 2024
MicroRNA-124-3p-enriched small extracellular vesicles as a therapeutic approach for Parkinson's disease
Marta Esteves1, Ricardo Abreu2, Hugo Fernandes3
1Health Sciences Research Centre (CICS-UBI), Faculty of Health Sciences, University of Beira Interior, 6200-506 Covilhã, Portugal.
Abstract:
Parkinson's disease is a neurodegenerative disease characterized by the loss of dopaminergic neurons in the substantia nigra with no effective cure available. MicroRNA-124 has been regarded as a promising therapeutic entity for Parkinson's disease due to its pro-neurogenic and neuroprotective roles. However, its efficient delivery to the brain remains challenging. Here, we used umbilical cord blood mononuclear cell-derived extracellular vesicles as a biological vehicle to deliver microRNA (miR)-124-3p and evaluate its therapeutic effects in a mouse model of Parkinson's disease. In vitro, miR-124-3p-loaded small extracellular vesicles induced neuronal differentiation in subventricular zone neural stem cell cultures and protected N27 dopaminergic cells against 6-hydroxydopamine-induced toxicity. In vivo, intracerebroventricularly administered small extracellular vesicles were detected in the subventricular zone lining the lateral ventricles and in the striatum and substantia nigra, the brain regions most affected by the disease. Most importantly, although miR-124-3p-loaded small extracellular vesicles did not increase the number of new neurons in the 6-hydroxydopamine-lesioned striatum, the formulation protected dopaminergic neurons in the substantia nigra and striatal fibers, which fully counteracted motor behavior symptoms. Our findings reveal a novel promising therapeutic application of small extracellular vesicles as delivery agents for miR-124-3p in the context of Parkinson's disease.
Insights
Extracellular vesicles carrying microRNA-124-3p protected brain cells and motor function in a Parkinson's disease mouse model. This novel delivery method shows promise for treating this neurodegenerative disorder.
Area of Science:
- Neuroscience
- Biotechnology
- Genetics
Background:
- Parkinson's disease (PD) involves progressive loss of dopaminergic neurons, lacking effective cures.
- MicroRNA-124 (miR-124) shows potential for PD therapy due to its neurogenic and neuroprotective properties.
- Efficient delivery of therapeutic agents like miR-124 to the brain is a significant challenge.
Purpose of the Study:
- To investigate the therapeutic potential of miR-124-3p delivered via extracellular vesicles (EVs) in a Parkinson's disease mouse model.
- To evaluate the neuroprotective and neurogenic effects of miR-124-3p loaded EVs in vitro and in vivo.
- To assess the biodistribution and therapeutic efficacy of EV-mediated miR-124-3p delivery in PD.
Main Methods:
- Umbilical cord blood mononuclear cell-derived EVs were loaded with miR-124-3p.
- In vitro studies involved neural stem cell differentiation and dopaminergic cell protection assays.
- In vivo studies utilized a 6-hydroxydopamine-induced Parkinson's disease mouse model, assessing EV biodistribution, neuronal survival, and motor behavior.
Main Results:
- In vitro, miR-124-3p-loaded EVs promoted neuronal differentiation and protected dopaminergic cells from toxicity.
- In vivo, EVs successfully reached key brain regions affected by PD, including the substantia nigra and striatum.
- EV-mediated miR-124-3p delivery protected dopaminergic neurons and striatal fibers, significantly improving motor function in PD mice.
Conclusions:
- Extracellular vesicles serve as effective biological vehicles for delivering miR-124-3p to the brain.
- EV-delivered miR-124-3p demonstrates significant therapeutic potential for Parkinson's disease by protecting neurons and restoring motor function.
- This approach offers a promising novel therapeutic strategy for Parkinson's disease treatment.
Related Concept Videos
01:24Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
01:22MicroRNAs
01:15Parkinson's Disease: Overview